{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:44:32Z","timestamp":1788857072544,"version":"build-2803163510"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Thromboembolic disease is associated with a high rate of disability or death and gravely jeopardizes people\u2019s health and places considerable financial pressure on society. The primary treatment for thromboembolic illness is anticoagulant medication. Fondaparinux, a parenteral anticoagulant medicine, is still used but is confusing due to its disparate domestic and international indications and lack of knowledge about its usage. Its off-label drug usage in therapeutic settings and irrational drug use are also common.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> The aim of this guideline is to enhance the judicious clinical application of fondaparinux by consolidating the findings of evidence-based research on the drug and offering superior clinical suggestions.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Seventeen clinical questions were developed by 37 clinical pharmacy experts, and recommendations were formulated under the supervision of three methodologists. Through methodical literature searches and the use of recommendation, assessment, development and evaluation grading techniques, we gathered evidence.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> This guideline culminated in 17 recommendations, including the use of fondaparinux for venous thromboembolism (VTE) prevention and treatment, perioperative surgical prophylaxis, specific diseases, special populations, bleeding and overdose management. For different types of VTE, we recommend first assessing thrombotic risk in hospitalized patients and then administering the drug according to the patient\u2019s body mass. In surgical patients in the perioperative period, fondaparinux may be used for VTE prophylaxis, but postoperative use usually requires confirmation that adequate hemostasis has been achieved. Fondaparinux may be used for anticoagulation prophylaxis in patients hospitalized for oncological purposes, in patients with atrial fibrillation (AF) after resuscitation, in patients with cirrhosis combined with portal vein thrombosis (PVT), in patients with antiphospholipid syndrome (APS), and in patients with inflammatory bowel disease (IBD). Fondaparinux should be used with caution in special populations, such as pregnant female patients with a history of heparin-induced thrombocytopenia (HIT) or platelet counts less than 50 \u00d7 10<jats:sup>9<\/jats:sup>\/L, pregnant patients with a prethrombotic state (PTS) combined with recurrent spontaneous abortion (RSA), and children. For bleeding caused by fondaparinux, dialysis may partially remove the drug.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The purpose of this guideline is to provide all healthcare providers with high-quality recommendations for the clinical use of fondaparinux and to improve the rational use of the drug in clinical practice. Currently, there is a lack of a dedicated antidote for the management of fondaparinux. The clinical investigation of activated prothrombin complex concentrate (APCC) or recombinant activated factor VII (rF\u2166a) as potential reversal agents is still pending. This critical gap necessitates heightened scrutiny and research emphasis, potentially constituting a novel avenue for future inquiries into fondaparinux sodium. A meticulous examination of adverse events and safety profiles associated with the utilization of fondaparinux sodium will contribute significantly to a more comprehensive understanding of its inherent risks and benefits within the clinical milieu.<\/jats:p>","DOI":"10.3389\/fphar.2024.1352982","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T11:07:22Z","timestamp":1710155242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)"],"prefix":"10.3389","volume":"15","author":[{"given":"Qinan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjiao","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li e","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/bjs.5154","article-title":"Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery","volume":"92","author":"Agnelli","year":"2005","journal-title":"Br. J. Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3760\/cma.j.issn.0253-2352.2016.02.001","article-title":"Chinese guidelines for the prevention of venous thromboembolism in major orthopaedic surgery","volume":"36","author":"Association","year":"2016","journal-title":"Chin. J. Orthop."},{"key":"B3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3760\/cma.j.issn.0376-2491.2018.06.003","article-title":"Chinese expert consensus on heparin-induced thrombocytopenia (2017)","volume":"98","author":"Association","year":"2018","journal-title":"Chin. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score","volume":"8","author":"Barbar","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/0961203319851863","article-title":"Four-year follow-up of two patients on maintenance therapy with fondaparinux and mycophenolate mofetil for microthrombotic antiphospholipid syndrome","volume":"28","author":"Baron","year":"2019","journal-title":"Lupus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/bjh.12314","article-title":"Anticoagulation for prevention and treatment of cancer-related venous thromboembolism","volume":"161","author":"Barsam","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1756284818793561","DOI":"10.1177\/1756284818793561","article-title":"Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician","volume":"11","author":"Basili","year":"2018","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejvs.2021.04.015","article-title":"Management and outcomes of patients with isolated superficial vein thrombosis under real life conditions (INSIGHTS-SVT)","volume":"62","author":"Bauersachs","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1161\/01.cir.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1365-2141.2003.04811.x","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers","volume":"124","author":"Bijsterveld","year":"2004","journal-title":"Br. J. Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"Cmaj"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"B\u00fcller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"B\u00fcller","year":"2004","journal-title":"Ann. Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.zefq.2017.10.008","article-title":"A reporting tool for practice guidelines in health care: the RIGHT statement","author":"Chen","year":"2017","journal-title":"Z Evid. Fortbild. Qual. Gesundhwes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.3760\/cma.j.cn112137-20200503-01410","article-title":"Guidelines for perioperative anesthesia management in elderly patients undergoing knee surgery (2020 edition)","volume":"100","author":"Chinese Society of Anesthesiology","year":"2020","journal-title":"Chin. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.acvd.2014.09.009","article-title":"SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study","volume":"108","author":"Cohen","year":"2015","journal-title":"Arch. Cardiovasc Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/jth.15217","article-title":"Monitoring of anticoagulation in thrombotic antiphospholipid syndrome","volume":"19","author":"Cohen","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"B21","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1160\/th12-08-0575","article-title":"Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats","volume":"109","author":"Corbonnois","year":"2013","journal-title":"Thromb. Haemost."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","article-title":"Fondaparinux for the treatment of superficial-vein thrombosis in the legs","volume":"363","author":"Decousus","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"10760296211014575","DOI":"10.1177\/10760296211014575","article-title":"Fondaparinux pre-peri-and\/or postpartum for the prophylaxis\/treatment of venous thromboembolism (FondaPPP)","volume":"27","author":"Dempfle","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.thromres.2008.07.007","article-title":"Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC","volume":"123","author":"Desmurs-Clavel","year":"2009","journal-title":"Thromb. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3760\/cma.j.issn.0376-2491.2018.36.002","article-title":"Chinese guidelines for the prevention and treatment of thrombotic diseases","volume":"98","author":"Diseases","year":"2018","journal-title":"Chin. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"Cd005134","DOI":"10.1002\/14651858.CD005134.pub3","article-title":"Pentasaccharides for the prevention of venous thromboembolism","volume":"10","author":"Dong","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1055\/s-0039-1677793","article-title":"Treatment of superficial vein thrombosis: a systematic review and meta-analysis","volume":"119","author":"Duffett","year":"2019","journal-title":"Thromb. Haemost."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3760\/cma.j.cn101441-20210715-00310","article-title":"Chinese expert consensus on the diagnosis and treatment of recurrent abortion complicated with prethrombotic state","volume":"41","year":"2021","journal-title":"Chin. J. Reproduction Contracept."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/s1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for Healthcare professionals from the neurocritical care society and society of critical care medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12893-022-01652-6","article-title":"Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study","volume":"22","author":"Fu","year":"2022","journal-title":"BMC Surg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00264-007-0360-7","article-title":"Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients","volume":"32","author":"Fuji","year":"2008","journal-title":"Int. Orthop."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1160\/th06-10-0577","article-title":"Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids","volume":"97","author":"Gerhardt","year":"2007","journal-title":"Thromb. Haemost."},{"key":"B37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.disamonth.2018.12.005","article-title":"Venous thromboembolism prophylaxis using the Caprini score","volume":"65","author":"Golemi","year":"2019","journal-title":"Dis. Mon."},{"key":"B38","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cgh.2019.05.056","article-title":"Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis","volume":"18","author":"Gu","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3969\/j.issn.1009-4393.2020.30.002","article-title":"Comparison of enoxaparin and fondaparinux in anticoagulant therapy during pregnancy in patients with recurrent abortion","volume":"26","author":"Guo","year":"2020","journal-title":"Contemp. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/iju.13189","article-title":"Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: a prospective randomized clinical trial","volume":"23","author":"Hata","year":"2016","journal-title":"Int. J. Urol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1007\/s00595-014-0911-7","article-title":"Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study","volume":"44","author":"Hata","year":"2014","journal-title":"Surg. Today"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0250096","DOI":"10.1371\/journal.pone.0250096","article-title":"Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: a PRISMA-compliant Bayesian network meta-analysis","volume":"16","author":"He","year":"2021","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-1-62703-339-8_8","article-title":"Activated partial thromboplastin time","volume":"992","author":"Ignjatovic","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/s1542-3565(05)00154-0","article-title":"Thrombosis and inflammatory bowel disease","volume":"3","author":"Irving","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5694\/mja2.50213","article-title":"Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the thrombosis and Haemostasis society of Australia and New Zealand HIT writing group","volume":"210","author":"Joseph","year":"2019","journal-title":"Med. J. Aust."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's choice - European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e012184","DOI":"10.1161\/jaha.119.012184","article-title":"Fondaparinux sodium compared with low-molecular-weight heparins for perioperative surgical thromboprophylaxis: a systematic review and meta-analysis","volume":"8","author":"Kumar","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"B53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40272-015-0120-x","article-title":"A guide to the use of anticoagulant drugs in children","volume":"17","author":"Law","year":"2015","journal-title":"Paediatr. Drugs"},{"key":"B54","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3969\/j.issn.1673-4254.2013.03.13","article-title":"Efficacy and safety of fondaparinux versus enoxaparin for preventing venous thromboembolism after major orthopedic surgery: a meta-analysis","volume":"33","author":"Li","year":"2013","journal-title":"J. SOUTH Med. Univ."},{"key":"B55","first-page":"822","article-title":"Interpretation of Chinese \"expert consensus on the diagnosis and treatment of recurrent abortion\" in 2016 and the European \"guidelines for the diagnosis and treatment of recurrent abortion\" in 2017","volume":"34","author":"Li","year":"2018","journal-title":"J. Pract. Obstetrics Gynecol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/s0392-9590.16.03765-2","article-title":"Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism","volume":"36","author":"Liew","year":"2017","journal-title":"Int. Angiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"B58","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3969\/j.issn.1000-8179.2019.13.765","article-title":"Guidelines for the prevention and treatment of tumor-related venous thromboembolism 2019 edition","volume":"46","author":"Ma","year":"2019","journal-title":"Chin. Clin. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/ej9.0000000000000038","article-title":"Choosing between enoxaparin and fondaparinux for the prevention of thromboembolism: a meta-analysis of randomized trials","volume":"9","author":"Mahdy","year":"2022","journal-title":"Egypt. J. Crit. Care Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines","volume":"22","author":"Mandal\u00e0","year":"2011","journal-title":"Ann. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"R154","DOI":"10.1186\/ar4616","article-title":"Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study","volume":"16","author":"Migita","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejogrb.2023.05.031","article-title":"Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: a meta-analysis","volume":"287","author":"Mu","year":"2023","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1253\/circj.cj-10-1036","article-title":"Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients","volume":"75","author":"Nakamura","year":"2011","journal-title":"Circ. J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/aap.0000000000000700","article-title":"Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (second edition): guidelines from the American society of regional anesthesia and pain medicine, the European society of regional anaesthesia and pain therapy, the American Academy of pain medicine, the international neuromodulation society, the north American neuromodulation society, and the world Institute of pain","volume":"43","author":"Narouze","year":"2018","journal-title":"Reg. Anesth. Pain Med."},{"key":"B65","article-title":"National Institute for health and care excellence: guidelines","volume-title":"Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism","author":"National Guideline","year":"2018"},{"key":"B66","volume-title":"Appendix 4 Quality of case series form 2015","year":"2020"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5758\/vsi.2018.34.1.1","article-title":"Extended-duration treatment of superficial vein thrombosis of the lower limbs with tinzaparin","volume":"34","author":"Nikolakopoulos","year":"2018","journal-title":"Vasc. Spec. Int."},{"key":"B68","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","article-title":"International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease","volume":"18","author":"Olivera","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B69","volume-title":"WHO handbook for guideline development","author":"Organization","year":"2014"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/eurheartj\/ehr218","article-title":"ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascular diseases during pregnancy of the European society of cardiology (ESC)","volume":"32","author":"Regitz-Zagrosek","year":"2011","journal-title":"Eur. Heart J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00776-010-0011-5","article-title":"Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery","volume":"16","author":"Sasaki","year":"2011","journal-title":"J. Orthop. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.thromres.2020.10.010","article-title":"Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management","volume":"198","author":"Sayar","year":"2021","journal-title":"Thromb. Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4103\/0259-1162.179313","article-title":"Perioperative considerations and management of patients receiving anticoagulants","volume":"11","author":"Shaikh","year":"2017","journal-title":"Anesth. Essays Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med. Res. Methodol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e28295","DOI":"10.1002\/pbc.28295","article-title":"FondaKIDS III: a long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children","volume":"67","author":"Shen","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1378\/chest.10-1944","article-title":"Predictive and associative models to identify hospitalized medical patients at risk for VTE","volume":"140","author":"Spyropoulos","year":"2011","journal-title":"Chest"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert Panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2021.0047","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B79","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/nejm200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement","volume":"344","author":"Turpie","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"Editor's choice - European society for vascular surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases","volume":"65","author":"Twine","year":"2023","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"B81","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in Meta-analyses\n            WellsG.\n            SheaB.\n            O\u2032ConnellD.\n            ale.\n          2020"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/circresaha.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ. Res."},{"key":"B83","volume-title":"Evidence retrieval and evaluation in evidence-based medicine","author":"Yang","year":"2018"},{"key":"B84","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12891-023-06674-6","article-title":"Comparison of the efficacy of low-molecular-weight heparin and fondaparinux sodium after total knee arthroplasty: a retrospective cohort study","volume":"24","author":"Yang","year":"2023","journal-title":"BMC Musculoskelet. Disord."},{"key":"B85","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3870\/j.issn.1004-0781.2022.05.001","article-title":"Interpretation of the 2021 edition of the asia-pacific consensus on venous thromboembolism in knee and hip arthroplasty and hip fracture surgery: pharmacoprophylaxis for venous thromboembolism","volume":"41","author":"Yin","year":"2022","journal-title":"Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/pbc.23011","article-title":"FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age","volume":"57","author":"Young","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e8256","DOI":"10.1097\/md.0000000000008256","article-title":"Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients","volume":"96","author":"Zhang","year":"2017","journal-title":"Med. Baltim."},{"key":"B88","doi-asserted-by":"publisher","first-page":"717630","DOI":"10.3389\/fendo.2021.717630","article-title":"Retrospective analysis of fondaparinux and low-molecular-weight heparin in the treatment of women with recurrent spontaneous abortion","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1352982\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T11:08:50Z","timestamp":1710155330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1352982\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":88,"alternative-id":["10.3389\/fphar.2024.1352982"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1352982","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"article-number":"1352982"}}